CLINICAL ROLE -
Data Show Rectal Administration of Fecal Microbiota for Recurrent CDI Safe, Simple for Routine Clinical Practice
With a new administration protocol created specifically for the routine clinic, infectious disease physicians can treat recurrent clostridioides difficile infection in less than 3 weeks.
RBX2660 Leads to Recurrent-Free Outcomes for Patients With Clostridioides difficile Infection
Among individuals who received systemic antibiotics within 8 weeks, 6 months, 12 months, and 24 months of receiving fecal microbiota, RBX2660 prevented recurrence.
Experts Assess Association of Recurrent Clostridioides Difficile with Gut Microbiota
Health-related quality of life scores were positively associated with log MHI and Bacteriodia, and negatively with Gammaproteobacteria and Bacilli.
Rebyota Found Safe, Effective in Preventing Recurring Clostridioides Difficile Infection
Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.
Pharmacists Are Being Recognized for Their Contributions to the Field of Infectious Disease
Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses being the second pharmacist in IDSA history to receive a society award and what this means not only for her, but for the field.
2 Commerce Drive Cranbury, NJ 08512